Lumiradx five-minute sars-cov-2 ag ultra test achieves ce marking

Results in just 5 minutes from sample application, aids in fast clinical decision-making at point of care (poc), helping to inform treatment decisions and prevent the further spread of infection, while also increasing testing throughput run on the multi-assay lumiradx platform, the ultra test's innovative strip design builds on the company's microfluidic immunofluorescence technology enabling faster reaction times without sacrificing sensitivity   available on the same poc platform as lumiradx's high sensitivity sars-cov-2 antigen, flu a/b, sars-cov-2 antibody, sars-cov-2 antigen pool as well as inr, d-dimer and crp tests* london , may 19, 2022 /prnewswire/ -- lumiradx limited (nasdaq: lmdx), a next-generation point of care diagnostics company, today announced its sars-cov-2 ag ultra test achieved ce marking. the ultra test provides digital and connected results in just five minutes with high sensitivity, making it one of the fastest and most sensitive covid-19 antigen tests available.
LMDX Ratings Summary
LMDX Quant Ranking